Technical Analysis for AKBA - Akebia Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| A | 1.69 | 1.81% | 0.03 |
AKBA closed up 1.81 percent on Friday, November 1, 2024, on 1.3 times normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Nov 6
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Shooting Star Candlestick | Bearish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Walk | Strength | 1.81% | |
| Inside Day | Range Contraction | 1.81% | |
| Wide Bands | Range Expansion | 1.81% | |
| Overbought Stochastic | Strength | 1.81% | |
| Calm After Storm | Range Contraction | -0.59% | |
| Doji - Bearish? | Reversal | -0.59% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 21 hours ago |
| Up 5% | about 21 hours ago |
| Up 1 ATR | about 21 hours ago |
| 2x Volume Pace | about 21 hours ago |
| Rose Above Previous Day's High | about 21 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/06/2024
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is AKB-6548, a HIF-PH inhibitor, which is in Phase IIb clinical trials for patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. The company is also developing a development program for patients dependent on dialysis. Akebia Therapeutics, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Kidney Disease Dialysis Anemia Chronic Kidney Disease Kidney Hypoxia Inducible Factors
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Biology Kidney Disease Dialysis Anemia Chronic Kidney Disease Kidney Hypoxia Inducible Factors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 2.48 |
| 52 Week Low | 0.8 |
| Average Volume | 1,590,188 |
| 200-Day Moving Average | 1.39 |
| 50-Day Moving Average | 1.43 |
| 20-Day Moving Average | 1.47 |
| 10-Day Moving Average | 1.62 |
| Average True Range | 0.08 |
| RSI (14) | 70.59 |
| ADX | 36.41 |
| +DI | 33.15 |
| -DI | 6.20 |
| Chandelier Exit (Long, 3 ATRs) | 1.51 |
| Chandelier Exit (Short, 3 ATRs) | 1.50 |
| Upper Bollinger Bands | 1.80 |
| Lower Bollinger Band | 1.14 |
| Percent B (%b) | 0.84 |
| BandWidth | 45.01 |
| MACD Line | 0.09 |
| MACD Signal Line | 0.06 |
| MACD Histogram | 0.0293 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.80 | ||||
| Resistance 3 (R3) | 1.80 | 1.78 | 1.78 | ||
| Resistance 2 (R2) | 1.78 | 1.75 | 1.77 | 1.77 | |
| Resistance 1 (R1) | 1.73 | 1.73 | 1.72 | 1.73 | 1.77 |
| Pivot Point | 1.71 | 1.71 | 1.70 | 1.70 | 1.71 |
| Support 1 (S1) | 1.66 | 1.68 | 1.65 | 1.66 | 1.61 |
| Support 2 (S2) | 1.64 | 1.66 | 1.63 | 1.61 | |
| Support 3 (S3) | 1.59 | 1.64 | 1.60 | ||
| Support 4 (S4) | 1.59 |
